MicroRNAs are a key factor in the globalization of tumor-host relationships

V F Chekhun1

  • 1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.

Experimental Oncology
|October 2, 2019
PubMed

Insights

MicroRNAs (miRNAs) are emerging as key regulators in cancer, influencing tumor development beyond gene mutations. These molecules act as conductors in the genetic-epigenetic orchestra, offering new therapeutic targets and diagnostic markers for malignancy.

Area of Science:

  • Molecular Oncology
  • Epigenetics
  • Cancer Biology

Background:

  • The post-genomic era is shifting cancer research focus from gene mutations to epigenetic factors.
  • MicroRNAs (miRNAs) are increasingly recognized for their role in regulating gene expression and cellular processes, including cancer development.

Purpose of the Study:

  • To review literature and present research on the role of miRNAs in forming the molecular phenotype of malignancy.
  • To explore miRNAs as conductors of genetic-epigenetic interactions in cancer.
  • To investigate miRNAs as potential diagnostic markers and therapeutic targets in cancer.

Main Methods:

  • Literature review of molecular oncology and epigenetic studies.
  • Analysis of miRNA expression profiles in breast cancer cell lines.
  • Comparative analysis of miRNA roles in varying degrees of malignancy.

Main Results:

  • MiRNAs significantly influence tumor cell initiation, proliferation, and apoptosis control.
  • MiRNAs act as a "conductor" coordinating genetic and epigenetic factors in malignancy.
  • MiRNAs are involved in balancing mechanisms in breast cancer cell lines.
  • Specific miRNA expression profiles serve as markers for malignancy.

Conclusions:

  • MiRNAs are crucial players in cancer development, impacting oncogene-oncosuppressor relationships and tumor-host interactions.
  • MiRNAs represent a novel class of biomarkers and therapeutic targets in oncology.
  • Further research into miRNA networks may lead to a reclassification of neoplastic diseases and new cancer therapies.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K